Induction of apoptosis by Miltefosine in Iranian strain of Leishmania infantum promastigotes

Iranian Journal of Parasitology

Volumn 4, Issue 2, 2009, Pages 23-31

  Khademvatan, S ^a   Gharavi, M J ^a   Akhlaghi, L ^a   Samadikuchaksaraei, A ^b   Oormazdi, H ^a   Mousavizadeh, K ^b   Hadighi, R ^a   Saki, J ^a  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Apoptosis; IC50; Iran; Leishmania infantum; Miltefosine

Indexed keywords

LIPOCORTIN 5; MILTEFOSINE; PHOSPHATIDYLSERINE;

APOPTOSIS; ARTICLE; CELL COUNT; CELL DIFFERENTIATION; CELL MEMBRANE; CELL PROLIFERATION; CELL SIZE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY TEST; DNA FRAGMENTATION; DRUG DETERMINATION; DRUG RESPONSE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; IC 50; IRAN; LEISHMANIA INFANTUM; LETHAL DOSE; NONHUMAN; PARASITE VIABILITY; PROMASTIGOTE;

LEISHMANIA DONOVANI; LEISHMANIA INFANTUM;

EID: 67651177783     PISSN: 17357020     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis. 2004;27(5):305-18.
2. Guerin PJ, Olliaro P, Sundar S et al. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis. 2002;2(8):494-501.
3. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet.2005;366 (9496):1561-77.
4. Desjeux P, Alvar J. Leishmania/HIV coinfections: epidemiology in Europe. Ann Trop Med Parasitol. 2003;97 Suppl 1:3-15.
5. Parvizi P, Mazloumi-Gavgani AS, Davies CR, Courtenay O, Ready PD. Two Leishmania species circulating in the Kaleybar focus of infantile visceral leishmaniasis, northwest Iran: implications for deltamethrin dog collar intervention. Trans R Soc Trop Med Hyg. 2008;102(9):891-7.
6. Santos DO, Coutinho CE, Madeira MF et al. Leishmaniasis treatment--a challenge that remains: a review. Parasitol Res. 2008;103(1):1-10.
7. Terwogt JM, Mandjes IA, Sindermann H, Beijnen JH, Ten Bokkel Huinink WW. Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer. Br J Cancer. 1999;79(7-8):1158-61.
8. Sundar S, Rosenkaimer F, Makharia MK, Goyal AK, Mandal AK, Voss A, Hilgard P, Murray HW. Trial of oral miltefosine for visceral leishmaniasis. Lancet. 1998;352(9143):1821-3.
9. Soto J, Toledo J, Gutierrez P, Nicholls RS, Padilla J, Engel J, Fischer C, Voss A, Berman J. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis. 2001;33(7): 57-61.
10. Duijsings D, Houweling M, Vaandrager AB, Mol JA, Teerds KJ. Hexadecylphosphocholine causes rapid cell death in canine mammary tumour cells. Eur J Pharmacol. 2004; 502(3):185-93.
11. Esmaeili J, Mohebali M, Edrissian GH, Rezayat SM, Ghazi-Khansari M, Charehdar S. Evaluation of miltefosine against L. major (mrho/ir/ 75/er): in vitro and in vivo studies. Acta Medica Iranica. 2008; 4 (3):191-196.
12. Mohebali M, Fotouhi M, Hooshmand B, Zarei Z, Akhoundi B, Rahnema A, Razaghian AR, Kabir MJ, Nadim A. Comparison of miltefosime and meglumine antimoniate (GlucantimeR) for treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran. Acta Tropica. 2007; 103(1): 33-40.
13. Verma NK, Dey CS. Possible mechanism of miltefosine-mediated death of Leishmania donovani. Antimicrob Agents Chemother. 2004;48(8):3010-5.
14. Hamann A, Brust D, Osiewacz HD. Apoptosis pathways in fungal growth, development and ageing. Trends Microbiol. 2008; 16(6):276-83.
15. Wanderley JL, Benjamin A, Real F, Bonomo A, Moreira ME, Barcinski MA. Apoptotic mimicry: an altruistic behavior in host/Leishmania interplay. Braz J Med Biol Res. 2005;38(6):807-12.
16. Paris C, Loiseau PM, Bories C, Bréard J. Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes. Antimicrob Agents Chemother. 2004; 48(3):852-9.
17. Chowdhury AR, Mandal S, Goswami A, Ghosh M, Mandal L, Chakraborty D, Ganguly A, Tripathi G, Mukhopadhyay S, Bandyopadhyay S, Majumder HK. Dihydrobetulinic acid induces apoptosis in Leishmania donovani by targeting DNA topoisomerase I and II: implications in antileishmanial therapy. Mol Med. 2003;9(1-2):26-36.
18. Verma NK, Singh G, Dey CS. Miltefosine induces apoptosis in arsenite-resistant Leishmania donovani promastigotes through mitochondrial dysfunction. Exp Parasitol. 2007;116(1):1-13.
19. Samadikuchaksaraei A, Mousavizadeh K. High-tech biomedical research: lessons from Iran's experience. Biomed Eng Online. 2008;7:17.
20. Schriefer A, Wilson ME, Carvalho EM. Recent developments leading toward a paradigm switch in the diagnostic and therapeutic approach to human leishmaniasis. Curr Opin Infect Dis. 2008;21(5):483-8.
21. Alvar J, Aparicio P, Aseffa A, Den Boer M, Cañavate C, Dedet JP, Gradoni L, Ter Horst R, López-Vélez R, Moreno J. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev. 2008;21(2):334-59
22. Ashutosh, Sundar S, Goyal N. Molecular mechanisms of antimony resistance in Leishmania. J Med Microbiol. 2007;56:143-53
23. Palumbo E. Oral miltefosine treatment in children with visceral leishmaniasis: a brief review. Braz J Infect Dis. 2008;12(1):2-4.
24. Wöhrl S, Schnedl J, Auer H, Walochnik J, Stingl G, Geusau A. Successful treatment of a married couple for American leishmaniasis with miltefosine. J Eur Acad Dermatol Venereol. 2008; 22 (2):258-9.
25. Arnoult D, Akarid K, Grodet A, Petit PX, Estaquier J, Ameisen JC. On the evolution of programmed cell death: apoptosis of the unicellular eukaryote Leishmania major involves cysteine proteinase activation and mitochondrion permeabilization. Cell Death Differ. 2002;9(1):65-81.
26. Mukherjee SB, Das M, Sudhandiran G, Shaha C. Increase in cytosolic Ca2+ levels through the activation of non-selective cation channels induced by oxidative stress causes mitochondrial depolarization leading to apoptosis-like death in Leishmania donovani promastigotes. J Biol Chem. 2002; 277(27):24717-27.